Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
Adrian Streinu‐Cercel, Oana Săndulescu, Liliana Preoțescu, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 4
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis
Behnam Amani, Bahman Amani
Journal of Medical Virology (2022) Vol. 95, Iss. 2
Open Access | Times Cited: 93
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, et al.
Cochrane library (2022) Vol. 2022, Iss. 6
Open Access | Times Cited: 40
Monoclonal antibody levels and protection from COVID-19
Eva Stadler, Martin Burgess, Timothy E. Schlub, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 35
Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis
Karen M Elias, Shanchita R. Khan, Eva Stadler, et al.
The Lancet Microbe (2024) Vol. 5, Iss. 5, pp. e459-e467
Open Access | Times Cited: 11
The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis
Shivani Singh, Simon Boyd, William HK Schilling, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 5, pp. 935-945
Open Access | Times Cited: 9
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 9
Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options
Maria Chiara Pelle, Isabella Zaffina, Stefania De Luca, et al.
Life (2022) Vol. 12, Iss. 10, pp. 1605-1605
Open Access | Times Cited: 36
Outpatient randomized controlled trials to reduce COVID‐19 hospitalization: Systematic review and meta‐analysis
David J. Sullivan, Daniele Focosi, Daniel F. Hanley, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 12
Open Access | Times Cited: 21
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
Jin Yong Kim, Oana Săndulescu, Liliana Preoțescu, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 8
Open Access | Times Cited: 21
Outpatient regimens to reduce COVID-19 hospitalisations: a systematic review and meta-analysis of randomized controlled trials
David J. Sullivan, Daniele Focosi, Daniel F. Hanley, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 16
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1)
Amir Qaseem, Jennifer Yost, Matthew C. Miller, et al.
Annals of Internal Medicine (2022) Vol. 176, Iss. 1, pp. 115-124
Open Access | Times Cited: 16
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
Jonathan Bordat, Sébastien Maury, Mathieu Leclerc
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Therapeutic developments for SARS-CoV-2 infection—Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice
Oana Săndulescu, Cătălin Apostolescu, Liliana Preoțescu, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 9
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians
Isolde Sommer, Andreea Dobrescu, Dominic Ledinger, et al.
Annals of Internal Medicine (2022) Vol. 176, Iss. 1, pp. 92-104
Open Access | Times Cited: 15
Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
Greta Santi Laurini, Nicola Montanaro, Domenico Motola
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 34-34
Open Access | Times Cited: 14
Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: A living systematic review and meta-analysis
Su‐Yeon Yu, Miyoung Choi, Chelim Cheong, et al.
Journal of Microbiology Immunology and Infection (2023) Vol. 56, Iss. 5, pp. 909-920
Open Access | Times Cited: 8
Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: A systematic review and meta-analysis
Karen M Elias, Shanchita R. Khan, Eva Stadler, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications
Ashutosh Vashisht, Vishakha Vashisht, Harmanpreet Singh, et al.
Viruses (2024) Vol. 16, Iss. 8, pp. 1183-1183
Open Access | Times Cited: 2
Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19
Taeyun Kim, Dong-Hyun Joo, Seung Woo Lee, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 5, pp. 1412-1412
Open Access | Times Cited: 11
Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
Susin Park, Nam Kyung Je, Dong Wan Kim, et al.
Journal of Korean Medical Science (2022) Vol. 37, Iss. 13
Open Access | Times Cited: 11
Monoclonal antibody levels and protection from COVID-19
Eva Stadler, Martin Burgess, Timothy E. Schlub, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 10
Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
Young Rock Jang, Yoon Ju Oh, Jin Yong Kim
International Journal of Infectious Diseases (2023) Vol. 130, pp. 94-100
Open Access | Times Cited: 5
Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis
Mingyang Yang, Toni Li, Lihai Jiang, et al.
Journal of Infection (2022) Vol. 85, Iss. 4, pp. e122-e124
Open Access | Times Cited: 8
Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
Haein Kim, Young Rock Jang, Ji Yeon Lee, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top